Short-term double-blind evaluation of flunisolide aerosol for steroid-dependent asthmatic children and adolescents.

Chest
Gail G ShapiroC W Bierman

Abstract

The purpose of this study was to compare the effectiveness of flunisolide aerosol prescribed as .5 mg (two inhalations) twice daily and placebo in terms of oral steroid sparing ability in a population of 32 known steroid-dependent children and adolescents. Patients were stabilized on the lowest tolerated dose of daily AM or alternate AM oral corticosteroid for at least one month before entering the study. They were randomly assigned to either flunisolide or placebo treatment for the 12-week, double-blind trial. Patients were seen every two weeks for symptom assessment, physical examination, and pulmonary function testing. Tests of adrenal function were done initially and at the study's conclusion. The flunisolide group had improved asthma control compared with the placebo group. The daily oral steroid requirement decreased in 100 percent of the flunisolide group compared with 53 percent of the placebo group (P less than .01). Pulmonary function and endocrine function remained stable for both groups. There were no adverse effects. Flunisolide aerosol in doses of .5 mg twice daily appears to be topically active and to have oral steroid potential without apparent adverse effects.

References

Aug 1, 1978·The Journal of Allergy and Clinical Immunology·E Bacal, R Patterson

❮ Previous
Next ❯

Citations

Jan 1, 1984·Pharmacology & Therapeutics·R L Juliano
Aug 7, 2008·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Anwar K Abdullah, Salman Khan
Jun 12, 2004·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Kathleen Ververeli, Bradley Chipps
Mar 1, 1993·Archives of Disease in Childhood·P IlangovanJ O Warner
Jan 1, 1983·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·R S Zeiger
Jun 15, 2010·Pulmonary Pharmacology & Therapeutics·Kevin R Murphy
Nov 1, 1989·The Journal of Pediatrics·S R Wynn
Nov 3, 1998·The Journal of Allergy and Clinical Immunology·H A Boushey
Jan 1, 1989·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·J A Zora
Jan 1, 1985·The Journal of International Medical Research·J DryB Paramelle
Nov 1, 1984·Pharmacotherapy·C S Tse, I L Bernstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.